Full-Time
Posted on 11/5/2024
Biotechnology tools for genomic research
$113.5k - $153.5kAnnually
Senior, Expert
Remote in USA
Candidates should ideally be based in Maryland.
You match the following 10x Genomics's candidate preferences
Employers are more likely to interview you if you match these preferences:
10x Genomics develops products that enhance genomic research, focusing on single-cell analysis, spatial gene expression, and immune profiling. Their tools allow researchers to examine genetic information in detail, which is crucial for understanding complex biological systems. The company serves academic, clinical, and pharmaceutical researchers, providing advanced laboratory equipment, consumables like reagents and microfluidic chips, and software for data analysis. Unlike competitors, 10x Genomics specializes in high-resolution genomic data, catering to the growing demand for personalized medicine. Their goal is to support researchers in their quest to uncover insights into the human genome and develop new treatments.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$214.9M
Headquarters
Pleasanton, California
Founded
2012
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health benefits
Generous time off
Parental leave
FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentiallyPLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024.Preliminary, Unaudited Select Fourth Quarter 2024 Financial ResultsRevenue of approximately $165.0 million for the three months ended December 31, 2024 , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period.for the three months ended , representing 9% growth sequentially and a 10% decrease as compared to the corresponding prior year period. Instruments revenue of approximately $24.4 million , representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately $10.9 million of Chromium instruments revenue and $13.4 million of Spatial instruments revenue., representing 28% growth sequentially and a 37% decrease as compared to the corresponding prior year period. Instruments revenue consists of approximately of Chromium instruments revenue and of Spatial instruments revenue
Artificial intelligence continues to push the boundaries of science and health exploration. From mapping proteins to neurological networks, these systems continue to make game-changing impacts on the sector. This month, a group of advantageous researchers from the Institute of Psychiatry, Psychology & Neuroscience took AI integration further. They released a study in which AI algorithms were used to predict the metabolic age of patients. Here's what you need to know.Chronological Clock vs Biological ClockTo grasp the importance of this development, it's vital to understand the differences between your chronological and biological age. These two methods of determining the age of your body are used in different ways by healthcare professionals
PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health
PLEASANTON, Calif., Jan. 2, 2025 /PRNewswire/ - 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 7:30 a.m. Pacific Time.
"Yesterday, the Court issued its ruling on the post-trial motions that followed the November 2023 jury verdict in the patent infringement case between NanoString and 10x Genomics.
PLEASANTON, Calif., Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023.The injunction, which the Court said it will enter in January 2025, is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023
To overcome this challenge, 10X Genomics introduced the On-Chip Multiplex (OCM) solution, enabling multiplexing directly on the chip and eliminating the need for complex sample preparation, thus reducing handling time.
PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue single cell analysis for more applications.These launches are part of the company's strategy to drive widespread adoption of single cell analysis by lowering customer costs in multiple directions: per cell, per sample, per experiment and per project. With these advances, 10x Genomics is addressing the growing demand for high-throughput single cell applications and providing cost-effective offerings to help new researchers getting started in single cell and existing labs looking to scale up their research."These launches are an integral part of our ongoing push to democratize single cell analysis and make it more accessible and more affordable for more researchers than ever before," said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. "They add to a growing list of new single cell products, protocols and capabilities that make 2024 the most exciting year of Chromium innovation in the platform's history
PLEASANTON, Calif., Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024.Preliminary Select Third Quarter 2024 ResultsRevenue of approximately $151.7 million for the third quarter ended September 30, 2024 , representing an approximate 1% decrease from the corresponding prior year period.for the third quarter ended , representing an approximate 1% decrease from the corresponding prior year period. Preliminary revenue by source for the third quarter is expected to be as follows: Instruments revenue of approximately $19.1 million , representing a 46% decrease from the corresponding prior year period. Instruments revenue consists of approximately $7.6 million of Chromium instruments revenue and $11.4 million of Spatial instruments revenue. Consumables revenue of approximately $126.2 million , representing 10% growth over the corresponding prior year period
The decision came after 10X Genomics revealed plans at an industry event to introduce new Single Cell (SC) products in the fourth quarter.